Incyte (INCY) PT Raised to $99 at Oppenheimer After Topical Ruxolitinib Met Its Primary Endpoint
Tweet Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Incyte (NASDAQ: INCY) to $99.00 (from $96.00) while maintaining a Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
